BioNTech reported positive Phase 2 results for trastuzumab pamirtecan (BNT323), an antibody-drug conjugate (ADC) it plans to advance with an FDA filing. The company said the clinical readout supports continued development and is intended to support regulatory discussions. The ADC is positioned within a competitive HER2 market where established therapies are already in use, and BioNTech is signaling intent to pursue populations where it may differentiate. BioNTech said the company expects to pursue a regulatory pathway based on the Phase 2 dataset. For the ADC field, the Phase 2 milestone adds to the accumulating evidence base for new HER2-targeted payload and linker strategies. It also highlights how companies are leveraging interim and mid-stage data to accelerate filing timelines. Investors will likely focus on durability, safety, and which patient subsets demonstrate the cleanest efficacy signals as the program moves from trial results to regulatory engagement.